Tenosynovial giant cell tumors are a rare, locally aggressive neoplasm that is driven by an overexpression of colony-stimulating factor 1 (CSF1), a genetic anomaly which secretes a protein into the ...

The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, safety, and impact on patient quality of life.

Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...

BioWorld Content on 'tenosynovial giant cell tumors'Synox Therapeutics Ltd. has raised $75 million in a series B round to fund phase III development of emactuzumab, an antibody in-licensed from Roche ...

Source Reference: Gelderblom H, et al "Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial" Lancet ...

From The New England Journal of Medicine, Tap W, et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor, Volume 373, Pages 428-437.

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical ...

Among the 7MM, the United States had the highest prevalence of tenosynovial giant cell tumor, accounting for approximately 45% of total cases. In 2023, localized TGCT in the U.S. was most commonly ...

Tenosynovial giant cell tumor is a rare condition of the joint that can cause symptoms like pain, swelling, and limited movement. Exercise tips from a physical therapist may help you maintain ...

An investigational drug, PLX3397 (Plexxikon, Daiichi Sankyo), has shown prolonged tumor regression in patients with tenosynovial giant cell tumor (TGCT), a rare disorder of the joints that leaves ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT).